NCT01014741View on ClinicalTrials.gov

Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation

NACompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Persistent Atrial Fibrillation
Interventions
DRUG

Ibutilide

0.25mg IV ibutilide after PV isolation prior to CFE ablation

DRUG

Placebo

Placebo after PV isolation prior to CFE ablation.

Trial Locations (7)

10029

Icahn School of Medicine at Mount Sinai, New York

22908

University Of Virginia Health System, Charlottesville

95823

Regional Cardiology Associates, Sacramento

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

Unknown

Republic of Korea University Medical Center, Seoul

Sponsors

Collaborators (1)

Abbott Medical Devices
All Listed Sponsors
collaborator

Abbott Medical Devices

INDUSTRY

lead

Vivek Reddy

OTHER

NCT01014741 - Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation | Biotech Hunter | Biotech Hunter